Even if Italy's vote on austerity measures and the replacement for Prime Minister Silvio Berlusconi don't give you chest pains, London -based drug maker AstraZeneca (AZN) may be a safe place to hide. The maker of heart drug Crestor has seen its shares stay relatively flat since the beginning of 2008 even as the world's been gripped by a global financial crisis not seen since the Great Depression.
The company currently earns more than half of its $33.3 billion in annual sales from the Americas and has seen record operating profits of more than $11 billion since the financial crisis. Compared with rival Germany drugmaker Novartis (NVS), AstraZeneca has seen shares fall just over 1% this year compared with over 6% for the maker of Diovan. Out of $50.6 billion in annual sales, Novartis generates just 31% of sales from the U.S.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV